Company Description
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunetherapeutics targeting infectious diseases based on its proprietary arenavirus platform.
The company’s immuno-oncology pipeline includes HB-700, a novel next-generation multi-KRAS mutant-targeting investigational immunotherapy for the treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancers; Eseba-vec, an investigational immunotherapeutic agent in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers with enrollment completed in a Phase 1/2 clinical trial; and HB-300, which targets self-antigens for the treatment of prostate cancer.
It is also developing HB-400 for the treatment of Hepatitis B that is in Phase I of clinical trial; and HB-500 for the treatment of Human Immunodeficiency Virus (HIV) that is in Phase I of clinical trial.
The company has a collaboration and license agreement with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products for the treatment, cure, diagnosis, or prevention of the hepatitis B virus (HBV) and the HIV.
HOOKIPA Pharma Inc. was incorporated in 2011 and is headquartered in New York, New York.
| Country | United States |
| Founded | 2011 |
| IPO Date | Apr 18, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 87 |
| CEO | Malte Peters |
Contact Details
Address: 350 Fifth Avenue, 72nd Floor New York, New York 10118 United States | |
| Phone | 431 890 6360 |
| Website | hookipapharma.com |
Stock Details
| Ticker Symbol | HOOK |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $14.00 |
| CIK Code | 0001760542 |
| CUSIP Number | 43906K209 |
| ISIN Number | US43906K2096 |
| Employer ID | 81-5395687 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Malte Peters M.D. | Chief Executive Officer and Director |
| Mary Theresa Coelho M.B.A. | Executive Vice President, Chief Financial Officer, Compliance Officer and Director |
| Dr. Daniel D. Pinschewer M.D. | Co-Founder and Member of Scientific Advisory Board |
| Dr. Klaus Orlinger Ph.D. | Chief Scientific Officer |
| Dr. Mark Winderlich Ph.D. | Chief Research and Development Officer |
| Daniel Courtney | Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 28, 2025 | 10-K | Annual Report |
| Feb 20, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13D/A | Filing |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Jan 29, 2025 | 8-K | Current Report |
| Jan 10, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jan 10, 2025 | 8-K | Current Report |
| Jan 7, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jan 7, 2025 | 8-K | Current Report |
| Jan 2, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |